Product fact sheet
Hooga ULTRA360 Technical Profile
Hooga ULTRA360 specifications list 72 LEDs, 630/660/810/850 nm output, adjustable pulse controls, a 12.7 × 8.6 × 2.5 inch enclosure and AC 85–265 V input.
A compact four-wavelength ULTRA-series panel with 72 LEDs, pulse controls and a 116.4 W manual-listed electrical output figure.
compact four-wavelength comparisons, buyers comparing pulse/control documentation
buyers requiring independent output measurements, anyone treating manufacturer irradiance charts as third-party testing
Key tradeoff: The current manual is unusually information-dense, but its output and irradiance figures remain manufacturer documentation.
This is a factual fit-and-tradeoff summary, not a product recommendation. Formula, device and brand claims remain manufacturer claims unless the cited source is explicitly regulatory or independent testing.
Technical record
The 2025 ULTRA-series manual lists the ULTRA360 at 12.7 × 8.6 × 2.5 inches, with 72 LEDs, four nominal wavelengths—630, 660, 810 and 850 nm—and a 60° beam angle. It also documents adjustable pulse behavior and AC 85–265 V input.
The manual labels one field 360 W rated power and another 116.4 W output power. That wording should be preserved as manufacturer terminology; the latter should not be reinterpreted as independently measured optical radiant power.
Evidence boundary
The manual’s irradiance and coverage plots are manufacturer-generated. No compatible third-party common-protocol optical measurement is available for this model in the current record.
Its compact dimensions, four wavelength bands and pulse controls distinguish the hardware from the PRO300, but those features do not establish superior dose delivery or clinical effectiveness without comparable optical measurements and condition-specific evidence.
Technical specifications
Published specs and what they mean
Physical
- Dimensions
- 12.7 × 8.6 × 2.5 in Basis: Manufacturer manual 2025 ULTRA manual. Source: Hooga ULTRA Series User Manual (PDF)
Optical
- Wavelengths
- 630 / 660 / 810 / 850 nm Basis: Manufacturer manual 2025 ULTRA manual. Source: Hooga ULTRA Series User Manual (PDF)
- LED quantity
- 72 LEDs Basis: Manufacturer manual 2025 ULTRA manual. Source: Hooga ULTRA Series User Manual (PDF)
- Rated power
- 360 W Basis: Manufacturer manual Manufacturer rated-power label; not wall consumption or optical radiant power. Source: Hooga ULTRA Series User Manual (PDF)
- Beam angle
- 60° Basis: Manufacturer manual 2025 ULTRA manual. Source: Hooga ULTRA Series User Manual (PDF)
Electrical
- Manual-listed output power
- 116.4 W Basis: Manufacturer manual The manual labels this field 'Output Power'; Homeapotherapy preserves the label context rather than reclassifying it as measured optical power. Source: Hooga ULTRA Series User Manual (PDF)
- Power input
- AC 85–265 V Basis: Manufacturer manual 2025 ULTRA manual. Source: Hooga ULTRA Series User Manual (PDF)
Controls
- Pulse control
- 1–100 Hz adjustable; manufacturer presets described Basis: Manufacturer manual 2025 ULTRA manual; pulse availability is not efficacy evidence. Source: Hooga ULTRA Series User Manual (PDF)
What the current record does not establish
- No independent common-protocol optical measurement is normalized.
- The manual labels 116.4 W as output power; this record does not reinterpret that figure as optical radiant power.
- No Homeapotherapy hands-on testing exists.
A missing field is not evidence that the device lacks the feature or performs poorly. It means we do not currently have a sufficiently comparable, sourced value in the normalized record.
Source labels preserve provenance. Manufacturer specifications, ingredient lists and performance claims are not treated as independent clinical evidence; regulatory records and independent measurements are identified separately when available.
Dose and irradiance context
What the output number means over time
Fluence is a calculation, not a treatment recommendation. For continuous output, fluence in J/cm² equals irradiance in mW/cm² × seconds ÷ 1000. The calculation only remains meaningful at the measurement conditions used for the irradiance value.
No comparable independent average irradiance is normalized
This device may have a manufacturer-published irradiance claim, but Homeapotherapy does not calculate time-to-fluence from that number unless the current record contains a sufficiently defined independent area-average measurement. This avoids presenting unlike measurement methods as interchangeable.
What this calculation still cannot tell you
- whether this is an effective dose for any condition;
- how irradiance changes at a different distance or across curved anatomy;
- how much energy reaches tissue below the surface;
- whether a study used the same wavelength distribution, spot size, pulse mode or treatment schedule;
- whether peak irradiance would produce the same area exposure as the average value shown here.
Read Red Light Irradiance, Fluence and Dose Explained before trying to compare this output with a clinical paper or another panel.
Clinical evidence context
Where these wavelengths overlap with human research
Published device wavelengths: 630 / 660 / 810 / 850 nm.
This is a hardware-to-literature cross-reference, not a claim that this product treats any condition. A matching nominal wavelength does not reproduce a study's irradiance, dose, distance, treatment area, emitter geometry, schedule or patient population.
Research areas worth checking
- Pattern hair loss — human studies commonly use visible-red wavelengths, especially around the mid-600 nm range.
- Acne and inflammatory skin — red-light protocols exist, but acne studies may also use blue light and should not be generalized from panel specs.
- Skin rejuvenation and photoaging — visible-red and red/NIR LED protocols have been studied with varied devices and endpoints.
- Knee osteoarthritis — near-infrared wavelengths appear in the clinical literature, but wavelength alone does not establish an equivalent treatment protocol.
- Muscle recovery and musculoskeletal pain — research spans red and near-infrared bands with substantial protocol variation.
- Transcranial PBM and cognition — some research uses near-infrared wavelengths, but a body panel is not automatically equivalent to a head-targeted transcranial device.
- See the full wavelength-by-condition evidence chart for evidence strength, treatment geometry and major caveats.
Do not infer from wavelength overlap
- that this device is clinically proven for the linked condition;
- that more wavelengths are better;
- that the highest published irradiance is the best dose;
- that an open wound should be treated with a consumer device without appropriate wound assessment.
For wounds specifically, start with the wound-care safety decision guide before interpreting any device specification.
Safety first
What should make you slow down?
Follow the current ULTRA manual for eye protection, pulse controls and electrical use. Pulse features are hardware controls, not proof of better health outcomes.
- The manual includes eye-exposure and device-safety warnings.
- Manufacturer irradiance charts are not independent laboratory measurements.
Where to buy
Current tracked merchants
Commerce note: merchant economics never enter our editorial score. Affiliate links are identified as (paid link) and use sponsored-link markup.
No merchant destination is currently tracked for this product.
Source trail
Primary documents and supporting evidence
- Hooga ULTRA Series User ManualHooga · Manufacturer manual · PDF · retrieved 2026-08-11
- Hooga Quality & Certifications: What We Can VerifyHooga · Manufacturer · retrieved 2026-08-10
- Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] SubmissionsU.S. Food and Drug Administration · Regulatory · retrieved 2026-08-10